Navigation Links
Nektar Therapeutics Reports Financial Results for the First Quarter of 2012

SAN FRANCISCO, May 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2012.

Cash, cash equivalents, and investments at March 31, 2012 were $498.8 million as compared to $414.9 million at December 31, 2011.
This increase is primarily a result of the $124.0 million in proceeds received by Nektar for the sale of its Cimzia® and Mircera® royalty interests, which was completed during the first quarter of 2012.

"I am extremely pleased with Nektar's performance in the first quarter of 2012," said Howard W. Robin, President and Chief Executive Officer of Nektar. "We significantly strengthened our financial position with the sale of non-core royalties for $124 million with no equity dilution to our stockholders. We completed the Phase 1 clinical trials for NKTR-181, our novel opioid analgesic for chronic pain, and are targeting the start of the Phase 2 program in the middle of this year. In addition, we advanced our next new opioid candidate, NKTR-192 for acute pain, into Phase 1.  Finally, the FDA approved the eighth product enabled by Nektar technology, Affymax's OMONTYS® for anemia, showcasing the ability of our technology platform to continue to produce new product candidates in high value therapeutic areas."

The company also announced that the naloxegol clinical studies in opioid-induced constipation continue on-track for planned regulatory filings by AstraZeneca in mid-2013, and partner Baxter is targeting the start of Phase 3 development by year-end for BAX 855, a long-acting PEGylated Factor VIII therapeutic candidate for hemophilia A. 

Revenue for the first quarter of 2012 was $17.9 million, an increase versus $11.3 million in the first quarter of 2011. The increase was primarily due to higher product sales during the quarter.  Total operating costs and expenses in the first quarter of 2012 were $55.9 million as compared to $45.2 million in the first quarter of 2011.
Total operating costs and expenses increased primarily as a result of higher research and development expense and higher cost of goods for product sales.  Research and development expense in the first quarter of 2012 was $35.1 million as compared to $30.2 million for the first quarter of 2011.  R&D expense was higher in the first quarter of 2012 reflecting Nektar's focus on advancing a number of key clinical programs, including the Phase 3 study of etirinotecan pegol (NKTR-102) in metastatic breast cancer, the preparations to initiate the Phase 2 study for NKTR-181 in chronic pain patients, and the initial Phase 1 clinical study for NKTR-192. 

General and administrative expense was $10.4 million in the first quarter of 2012, a decrease as compared to $11.7 million in the first quarter of 2011. 

Net loss for the first quarter ended March 31, 2012 was $41.1 million or $0.36 loss per share.

The company also announced upcoming presentations at the following medical meetings and scientific congresses during the second and third quarters of 2012:

IMPAKT Breast Cancer Conference, Brussels, Belgium:

  • Abstract Title: "Phase 3 study of NKTR-102 versus Treatment of Physician's Choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC)", Cortes, J, et. al. 
  • Abstract/Poster Number: #173
  • Session Title/Track:  "New Drug Development"
  • Date: May 4, 2012, Gold Hall, 16:15 – 17:20 p.m. Central European Time
  • Abstract Title: "Significant antitumor activity in a randomized phase 2 study comparing 2 schedules of NKTR-102 in patients with metastatic breast cancer", Awada A, et. al.  
  • Abstract/Poster Number: #249
  • Session Title/Track:  "New Drug Development"
  • Date: May 4, 2012, Gold Hall, 16:15 – 17:20 p.m. Central European Time
  • American Society of Oncology (ASCO) Annual Meeting, Chicago, Illinois:

  • Abstract Title: "Phase 3 study of NKTR-102 versus Treatment of Physician's Choice (TPC) in pts with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane and capecitabine", Perez E, et. al. 
  • Abstract/Poster Number: #TPS1140/36A
  • Session Title/Track:  "Trials in Progress Session"
  • Date: June 2, 2012, 8:00 a.m. – 12:00 p.m. Central Time
  • Location: S Hall A2
  • Abstract Title: "NKTR-102 in patients with platinum-resistant ovarian cancer: Modeling CA-125 response and its correlation with tumor response", Chia Y, et. al. 
  • Abstract/Poster Number: #5048/18H
  • Session Title/Track:  "General Poster Session: Gynecologic Cancer"
  • Date: June 3, 2012, 8:00 a.m. – 12:00 p.m. Central Time
  • Location: S Hall A2
  • The International Conference on Opioids: Basic Science, Clinical Applications and Compliance

  • Abstract Title: "Multiple Dose Pharmacokinetics and Pharmacodynamics of the New Oral Opioid Analgesic, NKTR-181" Odinecs et. al. 
  • Abstract: #35
  • Date: June 12, 2012, 8:00 a.m. - 6:00 p.m. Eastern Time
  • Conference Call to Discuss First Quarter 2012 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) today, Wednesday, May 2, 2012.

    The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: The web broadcast of the conference call will be available for replay through June 2, 2012.

    To access the conference call, follow these instructions:Dial: (866) 203-3436 (U.S.); (617) 213-8849 (international)
    Passcode: 64392378 (Nektar Therapeutics is the host)An audio replay will also be available shortly following the call through Saturday, June 2, 2012 and can be accessed by dialing (888) 286-8010(U.S.); or (617) 801-6888 (international) with a passcode of 29485870.

    About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, has completed Phase 1 development and is being prepared for a Phase 2 study.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

    Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

    Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at

    Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods.  Examples of forward-looking statements include, among others, statements we make regarding our plans to initiate a Phase 2 clinical study for NKTR-181; AstraZeneca's planned regulatory filings with government health authorities for approval of NKTR-118 in one or more countries if the Phase 3 clinical studies for this drug candidate are successful; Baxter's planned start of Phase 3 development for BAX 855 prior to year-end;  the strength of our financial position and our future ability to invest in the advancement of our proprietary drug candidates; the value and potential of certain drug candidates being developed by our collaboration partners including NKTR-118 and OMONTYS®; and the value and potential of Nektar's technology and research and development pipeline.  Forward-looking statements are neither historical facts nor assurances of future performance.  Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements.  Therefore, you should not rely on any of these forward-looking statements.  Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our ability to maintain sufficient cash, liquid resources, and investments and our ability to raise additional cash through the monetization or sale of assets held by us or through one or more financing transactions that may be dilutive to our existing stockholders, in order to fund the repayment of the principal amount of the $215.0 million in outstanding convertible subordinated notes due in September 2012 and to allow us to further invest in our business; (ii) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (iii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; and (v) certain other important risks and uncertainties set forth in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2012.  Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made.  We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics(415) 482-5585Susan Noonan/SA Noonan Communications, LLC(212) 966-3650Nektar Media Inquiries:Karen Bergman/BCC Partners(650) 575-1509 Michelle Corral/BCC Partners(415) 794-8662 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(unaudited)ASSETS March 31, 2012  December 31, 2011 

    (1)Current assets:Cash and cash equivalents

    5,312Short-term investments

    233,624225,856Accounts receivable


    14,10812,656Other current assets

    13,63417,944Total current assets

    420,654276,706Long-term investments

    116,732173,768Property and equipment, net


    76,50176,501Other assets

    5,345999Total  assets

    ,550LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    3,019Accrued compensation

    8,18712,807Accrued expenses

    7,7596,669Accrued clinical trial expenses

    12,72611,953Deferred revenue, current portion

    20,00719,643Convertible subordinated notes

    214,955214,955Other current liabilities

    5,3586,486Total current liabilities

    270,753275,532Capital lease obligations, less current portion

    13,89014,582Liability related to sale of future royalties 

    125,785-Deferred revenue, less current portion

    111,050108,188Other long-term liabilities

    10,82410,437Total liabilities

    532,302408,739Commitments and contingenciesStockholders' equity:Preferred stock

    --Common stock

    1111Capital in excess of par value

    1,602,1411,597,428Accumulated other comprehensive loss

    (43)(1,103)Accumulated deficit

    (1,439,622)(1,398,525)Total stockholders' equity

    162,487197,811Total liabilities and stockholders' equity

    ,550(1) The consolidated balance sheet at December 31, 2011 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. 


     NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share information)(unaudited)Three Months Ended March 31, 20122011Revenue:Product sales and royalties

    $ 10,122$ 4,793License, collaboration, and other

    7,8276,506Total revenue

    17,94911,299Operating costs and expenses:Cost of goods sold

    8,7073,263Research and development

    35,08530,176General and administrative

    10,41411,727Impairment of long-lived assets

    1,675-Total operating costs and expenses

    55,88145,166Loss from operations

    (37,932)(33,867)Non-operating income (expense):Interest income

    632432Interest expense

    (4,333)(2,585)Other income, net

    660134Total non-operating expense

    (3,041)(2,019)Loss before provision for income taxes

    (40,973)(35,886)Provision for income taxes

    124148Net loss

    $ (41,097)$ (36,034)Basic and diluted net loss per share

    $ (0.36)$ (0.33)Weighted average shares used in computing basic and diluted net loss per share

    114,531108,677NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(In thousands)(unaudited)Three Months Ended March 31, 20122011Comprehensive Loss

    $ (40,037)$ (36,184) NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(unaudited)Three Months Ended March 31,20122011Cash flows from operating activities:Net loss 

    $ (41,097)$   (36,034)Adjustments to reconcile net loss to net cash used in operating activities:Non-cash interest expense on liability related to sale of future royalties 

    1,815-Stock-based compensation 

    4,2344,802Depreciation and amortization 

    3,4803,856Impairment of long-lived assets 

    1,675-Other non-cash transactions

    295309Changes in operating assets and liabilities:Accounts receivable 


    (1,452)(4,446)Other assets 

    4,305(1,199)Accounts payable 

    (1,290)(2,895)Accrued compensation 

    (4,620)(1,572)Accrued expenses 

    1,0941,961Accrued clinical trial expenses

    7731,505Deferred revenue 

    3,226(2,555)Other liabilities 

    (1,191)(1,544)Net cash used in operating activities 

    $ (34,618)$   (14,870)Cash flows from investing activities:Purchases of investments 

    (102,023)(372,723)Maturities of investments 

    151,964113,235Sales of investments

    -61,368Purchases of property and equipment 

    (1,516)(3,765)Net cash provided by (used in) investing activities 

    $   48,425$(201,885)Cash flows from financing activities:Payments of capital lease obligations 

    (566)(459)Proceeds from sale of future royalties, net of transaction costs

    119,589-Issuance of common stock, net of issuance costs

    479221,958Net cash provided by financing activities 

    $ 119,502$  221,499Effect of exchange rates on cash and cash equivalents 

    (136)(14)Net increase in cash and cash equivalents 

    $ 133,173$
    4,730Cash and cash equivalents at beginning of period

    15,31217,755Cash and cash equivalents at end of period

    $ 148,485$

    SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
    2. Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay
    3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
    4. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
    5. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
    6. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets
    7. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
    8. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
    9. Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
    10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
    11. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
    Post Your Comments:
    (Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
    (Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
    (Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
    Breaking Medicine Technology:
    (Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
    (Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
    (Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
    (Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
    (Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
    Breaking Medicine News(10 mins):